US pharma major Eli Lilly (NYSE: LLY) reported third-quarter 2016 financial results that disappointed Wall Street and saw the company’s share fall 1.5% to $76.40 in pre-market trading, although the stock levelled off to just a 0.26% fall just before close of trading.
Revenues for the three months were up 4.7% to $5.19 billion but fell short of the $5.35 billion expected by four analysts surveyed by Zacks Equity Research, as sales were hit by a disappointing performance of its Humalog insulin and animal health products
Lilly’s earnings were $778 million in the third quarter, down 1.5%. Adjusted results came in at $0.88 per share. On average, analysts expected earnings of $0.96 per share, according to Zacks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze